Novartis AG ADR

Novartis AG ADR

Yahoo Finance • 3 days ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist undergoing a significant turnaround. Novartis... Full story

Yahoo Finance • 3 days ago

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

VanEck Pharmaceutical ETF (NASDAQ:PPH) offers concentrated exposure to global drugmakers, while Vanguard Health Care ETF (NYSEMKT:VHT) provides a much broader, lower-cost entry point into the diverse healthcare landscape. Both funds targe... Full story

Yahoo Finance • 4 days ago

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Key Points Incyte has added to its pipeline through acquisitions. It anticipates four new approvals and launches through 2027. TG Therapeutics' shares are up more than 90% so far this year.10 stocks we like better than Incyte › Incyte(NA... Full story

Yahoo Finance • 5 days ago

Novartis Buys Myricx Bio in $1.5 Billion Deal

This article first appeared on GuruFocus. Novartis (NVS, Financials) a Swiss pharmaceutical company focused on prescription medicines, oncology, immunology and other major disease areas, agreed to acquire British biotech Myricx Bio in a d... Full story

Yahoo Finance • 6 days ago

European Stocks Close Mostly Lower in Monday Trading; Novartis to Acquire Myricx for Up to $1.5 Billion

The European stock markets closed mostly lower in Monday trading as The Stoxx Europe declined 0.4%, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 6 days ago

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday as Chip Stocks Rebound

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively tra PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 days ago

Novartis to Buy UK's Myricx Bio in $1.5 Billion Deal

Novartis (NVS) has agreed to acquire UK-based biotechnology firm Myricx Bio in a deal worth up to $1 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 days ago

Novartis To Acquire Myricx Bio In Deal Valued Up To $1.5 Bln, Expand Oncology Pipeline

(RTTNews) - Novartis AG (NVS) announced on Monday its agreement to acquire Myricx Bio, a UK-based biotechnology company developing a new class of antibody-drug conjugates, or ADCs, for up to $1.5 billion. Under the terms of the agreement,... Full story

Yahoo Finance • 7 days ago

Novartis strikes $1.5B deal for UK biotech Myricx Bio

[Novartis Corporate Building with Solar Panels] Ellads * Novartis (NVS [https://seekingalpha.com/symbol/NVS]) to acquire UK-based biotechnology company Myricx Bio, in a deal worth up to $1.5B, strengthening its oncology pipeline with a... Full story

Yahoo Finance • 7 days ago

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio's novel ADC assets and platform having b... Full story

Yahoo Finance • 7 days ago

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

Brandon Capital MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia's leading life sciences venture capital firm, today announces the successful exit of its portfolio company Myricx Bio following its agree... Full story

Yahoo Finance • 7 days ago

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

Myricx Bio Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of Novartis with Myricx Bio's novel ADC assets and platform having broad potenti... Full story

Yahoo Finance • 7 days ago

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis Pharma AG Adds potential first-in-class,N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis oncology pipeline with... Full story

Yahoo Finance • 8 days ago

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a more cost-efficient entry point and higher income potential, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) has recently demonstrated stronger price appreciation for investors seekin... Full story

Yahoo Finance • 8 days ago

New Research Says: The Biggest Gains of AI Won't Go to AI Stocks. These 2 ETFs Could Be Better Buys.

Who will be the biggest winners of the artificial intelligence (AI) boom? Some investors believe the AI hyperscalers will win by building AI tools, while other investors are betting on AI pick-and-shovel companies building AI infrastructur... Full story

Yahoo Finance • 8 days ago

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare is changing through AI and personalized cell therapy. Which of these high-growth innovators represents the better risk-adjusted opportunity for your portfolio today as you evaluate Heartflow Inc. (NASDAQ:HTFL) and Iovance Biothe... Full story

Yahoo Finance • 9 days ago

Novartis (SWX:NOVN) Stock Looks Cheap on Value But Pricey After 93% Return

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novartis stock has almost doubled investors' money over the past five years, yet current valuation checks still lean toward... Full story

Yahoo Finance • 10 days ago

[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Antidiabetic Drugs Market size & share revenue was valued at approximately USD 103.21... Full story

Yahoo Finance • 10 days ago

UK Cardiovascular Clinical Trials Market Projected to Reach USD 892.2 Million by 2033

Dublin, July 03, 2026 (GLOBE NEWSWIRE) -- The "UK Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report by Phase, Study Design, Indication, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's... Full story

Yahoo Finance • 10 days ago

European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally

European stock markets closed higher Thursday, paced by defense and luxury goods, while oil prices f PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story